Price list for foreign citizens - laboratory research methods

Laboratory diagnostics

	Name of the service	Unit of measurement	Rate No VAT	The cost of supplies	Total cost
1	2	3	4	5	6
	General clinical studies
3.1.6.	Determination of osmotic resistance of red blood cells by the photometric method	Study	24.31	1.37	25.68
	Research
	Hemostasiogram (paragraphs 1.2. + 1.4.1. + 1.5. + 6.40.1. + 6.40.2. + 6.40.3. + 6.6.4.)*	Study	22.20	30.99	53.19
	Coprogram (paragraphs 1.2. + 2.8.1. + 2.8.2. + 2.8.3.)	Study	27.63	7.95	35.58
	General blood test with platelets (paragraphs 1.2.+ 1.4.+ 3.7.+ 3.9.1.+ 3.26.3.+ 3.6.1.)*	Study	50.07	6.64	56.71
	General blood test (paragraphs 1.2.+ 1.4 ..+ 3.7.+ 3.9.1.+ 3.26.3.)	Study	31.98	6.10	38.08
	General urine analysis (paragraphs 1. 2. +2. 1. 9. +2. 1. 4. 1. +2. 1.10. 1.)*	Study	18.07	2.71	20.78
	Determination of blood groups according to the system A on Cross-Cross, determination of the Rh factor (Clause 1.2.+P..1.4.2.+C.1.5.+Clause 7.2.)*	Study	25.79	9.61	35.40
	Rebraga test (paragraphs 1.2. + 1.4. + 1.5. + (5.13.3.1.3.) X2)	Study	15.73	3.93	19.66
	Screening test for determining syphilis (RPR-Carbon) (Clause 1.2.+ Clause 1.4.3.+ Clause 1.5.+ Clause 8.17.9.1.11)	Study	34.02	7.22	41.24
1.	Separate operations
1.1.2.	Pipeting semi -automatic dispensers	pipetting	0.22	0.07	0.29
1.1.3.	Pipeting by automatic dispensers	pipetting	0.09	0.07	0.16
1.2.*	Registration (preliminary and final) of the material, patient’s passport data and research results in journals and banks or PCs*	Registration	4.52	0.53	5.05
1.2.1.	Registration (provision of results by e -mail)*	Study	4.52	0	4.52
1.3.	Blood from a finger
1.3.2.	Taking blood from a finger for the entire spectrum of hematological studies in the concept of "general blood test", including a leukocyte formula	Study	4.01	3.03	7.04
*1.3.1.	Taking blood from a finger (antibodies)	Study	1.92	1.08	3.00
1.4.	Vienna
	Registration + processing of venous blood to obtain plasma or serum *	Study	7.51	0.55	8.06
1.4.*	Blood sampling from a vein (biochemical blood test, UAC)*	Study	4.35	1.32	5.67
1.4.*	Blood sampling from a vein (biochemical blood test, UAC) **	Study	4.35	1.32	5.67
1.4.*	Blood fence from vein (biochemical blood test, UAC) ***	Study	4.35	1.32	5.67
1.4.*	Blood fence from vein (biochemical blood test, UAC) ****	Study	4.35	1.32	5.67
1.4.1.	Blood sampling from a vein (hemostasiogram, many and other separate indicators of a swelling system)	Study	4.35	1.24	5.59
1.4.2.	Blood fence from vein (blood type, Rh factor, antibodies)	Study	4.35	1.44	5.79
1.4.3.	Blood sampling from Vienna (immunochemistry, hormones, oncarkers, if (chlamydia, APS, autoimmune tests))*	Study	4.35	1.24	5.59
1.4.3.	Blood sampling from Vienna (immunochemistry, hormones, oncarkers, if (chlamydia, APS, autoimmune tests)) **	Study	4.35	1.24	5.59
1.4.4.	Blood fence from vein (glycated hemoglobin, cardiodrica))	Study	4.35	1.24	5.59
1.5.	Celent blood processing to obtain plasma or serum*	Study	2.99	0.02	3.01
2.1.	Urine research
2.1.2.	Glucose detection with expess test in the urine	Study	2.50	1.00	3.50
2.1.3.1.	Detection of protein with an expess test in the urine	Study	2.50	1.00	3.50
2.1.4.1.	Determination of protein with sulfacylic acid in the urine*	Study	6.53	0.42	6.95
2.1.6.	Detection of ketone bodies with an express test in the urine	Study	2.50	1.00	3.50
2.1.7.	Detection of bilirubin with an express test in the urine	Study	2.50	1.00	3.50
2.1.8.	Detection of urobilin bodies with an express test in the urine	Study	2.50	1.00	3.50
2.1.9.	The study of the complex of parameters of general urine analysis by means of semi -automatic analyzers based on dry chemistry methods	Study	2.99	1.21	4.20
2.1.10.1.	Microscopic examination of sediment in the urine normally	Study	4.01	0.55	4.56
2.1.11.	Calculation of the number of uniform elements by Nechiporenko (urine analysis by Nechiporenko)	Study	14.59	0.39	14.98
2.1.12.	Determining the concentration ability of the kidneys by Zimnitsky	Study	10.06	0.03	10.09
2.10.	Detection of Trichomonas and Gonococci in the drugs of the separated genital organs painted with methylene blue according to gram
2.10.1.	Detection of Trichomonas, gonococci in the drugs of the separated genitourinary organs painted with methylene blue (gynecol. Mais on the flora of 1 hearth))	Study	17.37	0.24	17.61
2.10.2.	Detection of Trichomonas, Gonococci in the drugs of the separated genitourinary organs painted according to gram (gynecols. Mais on the flora of 1 hearth)	Study	22.70	0.93	23.63
2.2.	Study of spinal fluid
2.2.1.	Determination of color, transparency, relative density, fibrous film in the cerebrospinal fluid	Study	2.99	0.01	3.00
2.2.2.	Detection of protein by reaction of Pandy in the cerebrospinal fluid	Study	2.50	0.03	2.53
2.2.3.1.	Determination of protein with sulfacylic acid in cerebrospinal fluid	Study	6.04	0.10	6.14
2.2.4.	Determination of the number of cellular elements (cytosis) and their differentiated calculation in the native drug in the cerebrospinal fluid	Study	19.36	0.65	01.20
2.2.5.	Microscopic examination in a painted drug in cerebrospinal fluid	Study	15.20	1.09	16.29
2.3.	Research of exudates and transfer
2.3.1.	Determination of the number, character, color, transparency, relative density of exudants and Tansesuds	Study	2.02	0.33	2.35
2.3.2.	The detection of protein by reaction of the rivals of exudants and Tansesuds	Study	4.01	0.56	4.57
2.3.3.	Microscopic study	Study	31.16	2.04	33.20
2.4.	Sputum research
2.4.1.	Determination of the number, character, color, consistency, smell in sputum	Study	2.02	0.88	2.90
2.4.2.1.	Microscopic examination of sputum in a native drug	Study	8.55	1.18	9.73
2.4.2.2.	Microscopic examination in sputum in a painted drug	Study	10.06	0.58	10.64
2.4.3.2.	Microscopy on acid-resistant microbacteria in the drugs painted according to cylies-nilsen.	Study	22.15	1.28	23.43
2.7.	The study of synovial fluid
2.7.1.	Determination of physicochemical properties in synovial fluid	Study	4.01	1.90	5.91
2.7.2.	Microscopic examination with the calculation of the number of uniforms (cytosis) in the native drug in the synovial fluid	Study	15.57	0.34	15.91
2.7.3.	Microscopic examination in a painted drug in synovial fluid	Study	12.07	0.91	12.98
2.8.	Study of feces
2.8.1.	Determination of color, consistency, smell, impurities, mucus, pH in feces	Study	2.02	0.10	2.12
2.8.2.	Detection of blood in the feces (AT to NB Human)	Study	2.99	4.06	7.05
2.8.2.1.	Bleeding test in feces (Lactoferin, Transferin, Calpropoxin)	Study	2.99	48.06	51.05
2.8.3.	Microscopic examination of feces (in 3 drugs)	Study	18.11	3.28	21.39
2.8.4.1.	Detection of protozoa in feces (cryptosporidia)	Study	8.06	9.11	17.17
2.8.4.2.	Detection of protozoa in feces (lamblia)	Study	8.06	6.52	14.58
2.8.5.	Helminthic detection by the CATO method (1 drug) in feces	Study	11.05	0.36	11.41
2.9.	Study of feces for enterobiosis
2.9.1.	Study of scraping for enterobiosis (in 3 drugs)	Study	11.05	1.11	12.16
3.	Hematological studies
3.4.	Counting reticulocytes in the blood*	Study	14.04	2.21	16.25
3.5.	Calculation of red blood cells with basophilic grain in the blood	Study	16.10	0.56	16.66
3.6.1.	Counting blood platelets in painted strokes by phonio	Study	18.11	0.56	18.67
3.7.	Determining the rate of erythrocyte in the blood (ESR)	Study	2.02	1.91	3.93
3.9.1.	Calculation of a leukocyte formula with a description of the morphology of blood cells for non -hemological diseases	Study	7.04	0.56	7.60
3.13.	Calculation of LE cells by Novoselova	Study	63.27	2.45	65.72
3.14.1.	Blood examination for malaria parasites with the preparation of a thick drop	Study	25.30	1.53	26.83
3.14.2.	Blood examination for malaria parasites in painted smear	Study	21.52	1.53	23.05
3.26.3.	Blood test using hematological analyzers of automatic, with differentiation of the leukocyte formula	Study	14.04	1.79	15.83
5.10.1.	Determination of cardiomarkers by dry chemistry
5.10.1.2.	Troponin, Mioglobin, MV fraction of creative phosphokinase (quantitative definition of (simultaneous) cardiomarkers, dry chemistry method)	Study	34.20	39.45	73.65
5.10.2.	Determination of cardiomarkers by the immunochemical method
5.10.2.1.	Troponin is ultra -sensitive in venous blood (determination of cardiomarkers by the immunochemical method)	Study	34.17	13.63	47.80
5.10.2.2.	Mioglobin in venous blood (determination of cardiomarkers by the immunochemical method)*	Study	34.17	18.18	52.35
5.10.2.3.	KFK-MW (concentration by mass) in venous blood (determination of cardiomarkers by the immunochemical method)	Study	34.17	13.21	47.38
5.10.2.4.	BNP (cerebral sodium peptide) in venous blood (determination of cardiomarkers by the immunochemical method)	Study	34.17	43.61	77.78
5.10.2.5.	NT-PROBNP (pro-brain sodium-reuretic peptide) in venous blood (determination of cardiomarkers by the immunochemical method)*	Study	34.17	35.90	70.07
5.11.2.	Determination of carcomorkers (oncomarkers) by immuno -function analysis, automated calculation
5.11.2.1.	Alfa-phytoprotein (AFP) (determination of carcomorkers (oncomarkers) by immuno-function analysis, automated calculation)*	Study	20.11	13.05	33.16
5.11.2.2.	Chancerombreal antigen (KEA) (determination of carcomorkers (oncomarkers) by immuno -functional analysis, automated calculation*	Study	20.11	13.38	33.49
5.11.2.3.	CA 19-9 (determination of carcomorkers (oncomarkers) by immuno-function analysis, automated calculation)*	Study	20.11	27.11	47.22
5.11.2.4.	CA - 125 (determination of carcomorkers (oncomarkers) by immuno -function analysis, automated calculation)*	Study	20.11	26.56	46.67
5.11.2.5.	CA 15-3 (determination of carcomorkers (oncomarkers) by immunoeroferment analysis automated calculation)*	Study	20.11	27.25	47.36
5.11.2.6.	Prostatic antigen General (PSA) (determination of carcomorkers (oncomarkers) by immuno -functional analysis, automated calculation)*	Study	20.11	14.73	34.84
5.11.2.7.	Prostatic Antigen Free (St. PCA) (determination of carcomorkers (oncomarkers) by immuno -functional analysis, automated calculation)*	Study	20.11	16.79	36.90
5.11.2.8.	B-2-microglobulin	Study	20.11	8.38	28.49
5.11.2.9.	CA 242*	Study	20.11	13.98	34.09
5.11.2.10.	Cyfra 21-1*	Study	20.11	22.53	42.64
5.11.2.11.	He-4*	Study	20.11	28.84	48.95
5.11.2.12.	Determination of calcitonin	Study	20.11	08/15	35.19
5.13.3.1.	Conducting research using multi -channel biochemical autoanizers with non -dummy registration of research results
5.13.1.1.	Glycated hemoglobin (HB A1) (determination of the concentration of glycated hemoglobin)*	Study	1.92	7.52	9.44
5.13.3.1.1	Total protein (biochemical blood test)*	Study	1.92	0.34	2.26
5.13.3.1.2.	Albumin (biochemical blood test)*	Study	1.92	0.24	2.16
5.13.3.1.3.	Creatinine (biochemical blood test)*	Study	1.92	1.03	2.95
5.13.3.1.4.	Urea (biochemical blood test)*	Study	1.92	0.46	2.38
5.13.3.1.5.	Uric acid (biochemical blood test)*	Study	1.92	0.39	2.31
5.13.3.1.6.	General cholesterol (biochemical blood test)*	Study	1.92	0.47	2.39
5.13.3.1.7.	High density cholesterol (HDL) (biochemical blood test)*	Study	1.92	1.39	3.31
5.13.3.1.8.	LDL cholesterol LDL (LDL) (biochemical blood test)*	Study	1.92	3.80	5.72
5.13.3.1.9.	Serum glucose (biochemical blood test)*	Study	1.92	0.16	2.08
5.13.3.1.10.	General bilirubin (biochemical blood test)*	Study	1.92	0.21	2.13
5.13.3.1.11.	Direct bilirubin (biochemical blood test)*	Study	1.92	0.36	2.28
5.13.3.1.13.	Calcium (biochemical blood test)*	Study	1.92	0.45	2.37
5.13.3.1.14	Potassium (biochemical blood test)*	Study	1.92	0.99	2.91
5.13.3.1.15	Sodium (biochemical blood test)*	Study	1.92	0.99	2.91
5.13.3.1.16	Chlorides (biochemical blood test)*	Study	1.92	0.99	2.91
5.13.3.1.17	Phosphorus inorganic (biochemical blood test)*	Study	1.92	0.20	2.12
5.13.3.1.18	Alaninaminotransferase ALT (biochemical blood test)*	Study	1.92	0.31	2.23
5.13.3.1.19	AST ASPAPATAMINTRESSFERASE (Biochemical Blood Analysis)*	Study	1.92	0.33	2.25
5.13.3.1.20	Alpha-amylase in blood serum (biochemical blood test)*	Study	1.92	0.99	2.91
5.13.3.1.22	Pancreatic amylase (biochemical blood test)*	Study	1.92	4.75	6.67
5.13.3.1.23	Lipaza*	Study	1.92	1.24	3.16
5.13.3.1.24	Alkaline phosphatase (determination of activity) (biochemical blood test)*	Study	1.92	0.40	2.32
5.13.3.1.25	Gamma-glutamintranspeptidase GGTP (determination of activity) (biochemical blood test)*	Study	1.92	0.56	2.48
5.13.3.1.26	HBDH (determination of activity) (biochemical blood test)*	Study	1.92	1.02	2.94
5.13.3.1.27	Lactate dehydrogenase LDH (determination of activity) (biochemical blood test)*	Study	1.92	0.51	2.43
5.13.3.1.28	CFC creatine phosphokinase (determination of activity) (biochemical blood test)*	Study	1.92	0.88	2.80
5.13.3.1.29	KFK-MV (determination of activity) (biochemical blood test)*	Study	1.92	4.02	5.94
5.13.3.1.30	Serum iron in blood serum (level determination) (biochemical blood test)*	Study	1.92	2.31	4.23
5.13.3.1.31	Triglycerides (biochemical blood test)*	Study	1.92	0.96	2.88
5.13.3.1.32	Ferritin (biochemical blood test)*	Study	1.92	7.42	9.34
5.13.3.1.33	Transerrin (biochemical blood test)*	Study	1.92	5.92	7.84
5.13.3.1.34	Mioglobin (biochemical blood test)*	Study	1.92	16.61	18.53
5.13.3.1.35	Microalbumin in the urine*	Study	1.92	4.44	6.36
5.13.3.1.36	Magnesium (biochemical blood test)*	Study	1.92	0.66	2.58
5.13.3.1.37	Apoprotein A1 (biochemical blood test)*	Study	1.92	6.49	8.41
5.13.3.1.38	Apoprotein B (biochemical blood test)*	Study	1.92	6.05	7.97
5.13.3.1.41	Copper (biochemical blood test)*	Study	1.92	3.57	5.49
5.13.3.1.42	Alpha - 1 - antitripsin (biochemical blood test)	Study	1.92	14.46	16.38
5.13.3.1.43	Cerulloplasmin (biochemical blood test)*	Study	1.92	7.37	9.29
5.13.3.1.44.	Glucose (glucosotolerant test - GTT) 2 -multiple	Study	1.92	8.87	10.79
5.13.3.1.46	Fructosamine	Study	1.92	4.90	6.82
5.13.3.1.47	Tsistatin C*	Study	1.92	9.94	11.86
5.13.3.1.50	General iron -binding capacity (OHSSS, UIBC)*	Study	1.92	6.77	8.69
5.2.	Biochemical studies using photoelectrocolorimeters and single -channel biochemical automatic filmmers
5.2.7.	Determination of glucose in solid blood express method	Study	7.46	2.19	9.65
5.6.	Biochemical studies The determination of indicators of the acid-base state of the blood through automatic analyzers
5.6.	Determination of indicators of the acid-base state (COST)	Study	6.99	30.87	37.86
5.6.1.	Determination of indicators of the acid-base state of the blood through automatic analyzers (KSHS)	Study	6.99	30.91	37.90
5.9.1.	Determination of hormones by immuno -function analysis with automated calculation
5.9.1.1	Estradiol (determination of sex hormones) *	Study	7.80	7.83	15.63
5.9.1.1.2	Follicle -stimulating hormone (FSH) (determination of sex hormones) FG*	Study	7.80	7.83	15.63
5.9.1.1.3	Luteinizing hormone (determination of sex hormones) LH*	Study	7.80	7.83	15.63
5.9.1.1.4.	Progesterone (determination of sex hormones)	Study	7.80	7.83	15.63
5.9.1.1.5	Prolactin (determination of sex hormones) PLN*	Study	7.80	11.65	19.45
5.9.1.1.6.	Testosterone (determination of sex hormones) TCTN*	Study	7.80	14.26	06.22
5.9.1.1.7.	Chorionic gonadotropin or its beta-bomb (determination of sex hormones) hCG or B-hCCH*	Study	7.80	9.50	17.30
5.9.1.1.8.	Tireotropic hormone (TSH) (determination of hormones, thyroid gland) TTG*	Study	7.80	7.44	15.24
5.9.1.1.9.	Free thyroxine (determination of hormones, thyroid gland) ft4*	Study	7.80	5.32	13.12
5.9.1.1.10.	Free triiodothyronine (determination of hormones, thyroid gland) FT3*	Study	7.80	6.52	14.32
5.9.1.1.11.	Prokalcitonin (determination of hormones, other) PCCN	Study	7.80	47.18	54.98
5.9.1.1.12.	Cortisol (determination of hormones, other) KRL	Study	7.80	21.06	28.86
5.9.1.1.13.	Anti -TG antibodies to tyroglobulin (determination of hormones, thyroid gland) anti -TG*	Study	7.80	9.88	17.68
5.9.1.1.14.	DGEA -I4	Study	7.80	26.00	33.80
5.9.1.1.15.	17-ON progesterone	Study	7.80	7.32	15.12
5.9.1.1.16.	Determination of parathormone	Study	7.80	9.22	02/17
5.9.1.2.2.	Antibodies antibodies to thyrooperoxidase (determination of hormones, thyroid gland)*	Study	9.64	14.47	24.11
6.	Studies of hemostasis
6.6.4.	Determining the content of fibrinogen in plasma on an automatic coagulometer*	Study	2.57	6.87	9.44
6.31.	Determination of the lupus anticoagulant by the clotting method*	Study	54.40	26.88	81.28
6.34.	Determination of antitrombin III (AT III)	Study	31.64	26.24	57.88
6.37.	Determination of protein with an automatic coagulometer	Study	31.64	31.52	63.16
6.38.	Determination of protein S on an automatic coagulometer	Study	31.64	54.74	86.38
6.39.	Determination of D-Dimers*	Study	31.64	22.59	54.23
6.39.1.	Determination of D-Dimers with an express method (immunofluorescent analysis)	Study	31.64	20.26	51.90
6.40.1.	Determination of activated partial thromboplastin time on an automatic coagulometer (ACTVT)*	Study	2.58	3.72	6.30
6.40.2.	Determination of prothrombin time (PTV) with thromboplastin calcium mixture with the calculation of many	Study	2.58	12.47	15.05
6.40.2.1.	Determination of prothrombin time (PTV) with the calculation of many - express tests from capillary blood (finger)*	Study	2.58	8.00	10.58
6.40.3.	Determination of thrombin time (TV)	Study	2.58	6.16	8.74
6.40.4	Determination of anti-ha hemostasis factor	Study	2.58	22.86	25.44
7.	Immunological studies
7.2.	Determination of blood groups according to the AVO system in the cross, determination of the Rh factor	Study	13.92	6.87	20.79
7.4.	Determination of incomplete Rhesus antibodies by conglutination	Study	44.29	1.65	45.94
7.6.	Direct Cumbsa test	Study	50.61	2.23	52.84
7.7.	Indirect sample of kumbs	Study	88.57	5.27	93.84
7.16.2.1.	SRB General (determination of individual blood serum proteins with a turbidimetric method)*	Study	4.56	4.04	8.60
7.16.2.2.	SRB is ultra -sensitive (determination of individual blood serum proteins with a turbidimetric method)	Study	4.56	2.67	7.23
7.16.2.3	Immunoglobulin a*	Study	4.56	5.11	9.67
7.16.2.4	Immunoglobulin m*	Study	4.56	5.30	9.86
7.16.2.5	Immunoglobulin g*	Study	4.56	5.30	9.86
7.16.2.6	Immunoglobulin e*	Study	4.56	13.97	18.53
7.17.2.	Determining the activity of anti -o - o - streptolizine in blood serum latex test*	Study	2.99	4.47	7.46
7.19.2.1.1.	Determination of autoantiber towards class M cardiolipin (IGM) by immuno -function analysis, semi -automated calculation	Study	7.80	12.31	20.11
7.19.2.1.2.	Determination of autoantibodies to class G (IgG) cardiolipin method by immunoformal analysis, semi -automated calculation	Study	7.80	12.31	20.11
7.19.2.1.3.	Determination of autoantiber to beta 2-glycoprotein class M (IGM) by immuno-function analysis, semi-automated calculation	Study	7.80	12.31	20.11
7.19.2.1.4.	Determination of autoantiber towards beta2-glycoprotein class G (IgG) by immunofortment analysis, semi-automated calculation	Study	7.80	12.31	20.11
7.19.2.1.5.	Determination of autoantibodies to nucleosomes by immuno -function analysis, semi -automated calculation*	Study	7.80	12.91	20.71
7.19.2.1.6.	Determination of autoantel to double-chain DNA (DS-DNA)*	Study	7.80	12.34	20.14
7.19.2.1.7.	Determination of antinuclear antibodies (ANA)*	Study	7.80	12.34	20.14
7.19.2.1.8.	Determination of anticytoplasmic antibodies (anca)	Study	7.80	12.34	20.14
7.19.2.1.9.	Determination of antibodies to cyclical citrulinated peptide (ACCP)*	Study	7.80	14.59	22.39
7.19.2.1.10	Determination of autoantibodies to mitochondria (ama)	Study	7.80	12.29	09.20
7.19.2.1.11	Determination of autoantibodies to tissue transglutaminase IG A	Study	7.80	11.70	19.50
7.19.2.1.12	Determination of autoantiber to tissue transglutaminase IG G	Study	7.80	12.28	08.20
7.19.2.1.13.	Determination of antibodies to a modified citrulinized viementin (MCV)*	Study	7.80	17.75	25.55
7.19.2.1.14.	Determination of the rheumatoid factor IG M	Study	7.80	12.28	08.20
7.19.2.1.15	Determination of autoantibodies to myeloperoxidase (MRO)	Study	7.80	12.25	05.20
7.19.2.1.16	Determination of autoantiber to proteinase-3 (PR-3)	Study	7.80	13.65	21.45
7.19.2.1.17.	Determination of autoantibodies to the internal factor (KALEA)	Study	7.80	12.97	20.77
7.19.2.1.18.	Determination of antibodies to gliadin IG A (Anti-Gliadin Iga)	Study	7.80	12.05	19.85
7.19.2.1.19.	Determination of antibodies to gliadin IG G (Anti-Gliadin IgG)	Study	7.80	12.05	19.85
7.19.2.1.20.	Determination of antibodies to Saccaharomyces Cerevisiae A (ASCA IG A)	Study	7.80	12.05	19.85
7.19.2.1.21.	Definition of antibodies to Saccaharomyces Cerevisiae G (ASCA IG G)	Study	7.80	12.05	19.85
7.19.2.1.22.	Screening of antiphospholipid total antibodies (AT to cardiolipin, beta-2-glycoprotein-1, phosphotydilositol, phosphotididserin) class M Anti-Phospholipid Screen IgM*	Study	7.80	12.05	19.85
7.19.2.1.23.	Screening of antiphospholipid total antibodies (AT to cardiolipin, beta-2-glycoprotein-1, phosphotydilositol, phosphotididserin) class G Anti-Phospholipid Screen igg*	Study	7.80	12.25	05.20
7.19.2.1.24.	Determination of antibodies to phosphotylserin class m (AT to phosphotidylserin IG M)	Study	7.80	12.00	19.80
7.19.2.1.25.	Determination of antibodies to phosphotylserin class G (AT to phosphotidylserin IG G)	Study	7.80	12.00	19.80
7.19.2.1.26.	Determination of antibodies to Latoferrin (at-K Lacterrin)	Study	7.80	10.07	17.87
7.19.2.1.27.	Determination of antibodies to a soluble liver antigen (anti-sla)	Study	7.80	15.17	22.97
7.19.2.1.28.	Determination of antibodies to the microsomes of the liver and kidneys (Anti-LKM-1)	Study	7.80	15.15	22.95
7.19.2.1.29.	Determination of antibodies to the deaminated peptide of gliadine IG A (anti-dgp ig a)	Study	7.80	12.19	19.99
7.19.2.1.30.	Determination of antibodies to the deaminated peptide of gliadine Ig G (anti-dgp ig g)	Study	7.80	12.19	19.99
7.19.2.1.31.	Determination of antibodies to the parietal cells of the stomach IG G (anti-Parietal Cell IgG)	Study	7.80	12.24	04.20
7.19.2.1.32.	Determination of antibodies to the basal membrane of the Bloons IG G (Anti-GBM IgG)	Study	7.80	13.70	21.50
7.19.2.1.33.	Determination of antibodies (high-quality) ANA-immunoblotting class 9 parameters	Study	7.80	32.75	40.55
7.19.2.1.34.	Determination of antibodies (high -quality) -Miosite profile -immunoblotting	Study	7.80	32.75	40.55
7.19.2.1.35.	Determination of antibodies (high -quality) -anca profile -immunoblotting 3 parameters	Study	7.80	32.75	40.55
7.19.2.1.36.	Determination of vitamin D2/d3-OH*	Study	7.80	35.66	43.46
7.19.2.1.37.	Determination of antibodies (high-quality) class ANA-Immunoblotting17 parameters	Study	7.80	45.70	53.50
7.19.2.1.38.	Insulin definition*	Study	7.80	9.10	16.90
7.19.2.1.39.	Determination of vitamin in 12*	Study	7.80	15.23	23.03
7.19.2.1.40.	Determination of pyrilinks-D (bone resorption marker)	Study	7.80	44.18	51.98
7.19.2.1.41	Determination of osteocalcine	Study	7.80	19.65	27.45
7.19.2.1.42	Determination of the level of folates (vitamin B9, folic acid)*	Study	7.80	20.62	28.42
7.19.2.1.45	Determination of ELISA ANTI-SS-A (Reve.)	Study	7.80	19.26	27.06
7.19.2.1.46	Determination of ELISA ANTI-SS-B (Reve.)	Study	7.80	19.26	27.06
7.19.2.1.47	Determination of ELISA ANTI-SM (Reve.)	Study	7.80	19.26	27.06
7.19.2.1.48	Determination of ELISA ANTI-SS-A 52 (Reve.)	Study	7.80	19.26	27.06
7.19.2.1.49	Determination of ELISA ANTI-SS-A 60 (Reve.)	Study	7.80	19.26	27.06
7.19.2.1.50	Definition of Anti-Rnp/SM ELIS (Reve.)	Study	7.80	19.26	27.06
7.19.2.1.51	Determination of ELISA Anti-SCL-70 (Reve.)	Study	7.80	19.26	27.06
7.19.2.1.52	Determination of ELISA ANTI-CENTROMERE B (Reve.)	Study	7.80	19.26	27.06
7.19.2.1.53	Determination of ELISA ANTI-JO-1 (Reve.)	Study	7.80	19.26	27.06
7.21.2.	Rheumatoid factor (determination in the blood serum with a latex test)*	Study	2.99	3.22	6.21
8.	Bacteriological studies
8.3.1.	Microscopy of stained (according to gram) drugs of native material, sputum, flushing waters of the bronchi, transudates, exudates (studies on aerobic and optional anaerobic microorganisms)	Study	22.70	0.53	23.23
8.17.9.1.1.	Determination of antigens to Helicobacter pylori in feces (to viral and bacterial antigens method by immunofortment analysis with semi -automated calculations)	Study	22.15	11.66	33.81
8.17.9.1.2.	Determination of antibodies to Helicobacter pylori in the blood (to viral and bacterial antigens method by immunofortment analysis with semi -automated calculation)	Study	22.15	5.10	27.25
8.17.9.1.3.	Determination of antibodies (IgG) to the Varicella Zoster virus (to viral and bacterial antigens by immuno -function analysis with semi -automated calculations)	Study	22.15	6.59	28.74
8.17.9.1.4.	Determination of antibodies (IgM) to toxoplasm*	Study	22.15	7.04	29.19
8.17.9.1.5.	Determination of antibodies (IgG) to toxoplasm*	Study	22.15	7.80	29.95
8.17.9.1.6.	Determination of antibodies to cytomegalovirus (IgM CMV)*	Study	22.15	6.35	28.50
8.17.9.1.7.	Determination of antibodies to cytomegalovirus (IgG CMV)*	Study	22.15	6.26	28.41
8.17.9.1.8.	Determination of IgG to the early capsid antigen of the Epstein Barra virus (EBV VCA/EA IgG)	Study	22.15	10.05	32.20
8.17.9.1.9.	Determination of IGM to the capsid antigen of the Epstein Barra virus (EBV VCA IgM)	Study	22.15	10.05	32.20
8.17.9.1.10.	Determination of IgG to the nuclear antigen of the Epstein Barra virus (EBV Ebna IgG)	Study	22.15	9.40	31.55
8.17.9.1.11.	Screening test for determining syphilis (RPR-Carbon)	Study	22.15	5.43	27.58
8.17.9.1.12.	Determination of antibodies (IgG) to the hepatitis C virus (Anti-HCV)*	Study	22.15	13.61	35.76
8.17.9.1.13.	Determination of high -quality superficial antigen of the hepatitis B (HBS AG Ultra)**	Study	22.15	16.57	38.72
8.17.9.1.14	Determination of antibodies (IgM) to rubella (Rubella)*	Study	22.15	6.63	28.78
8.17.9.1.15	Determination of antibodies (IG G) to rubella (Rubella)*	Study	22.15	7.03	29.18
8.17.9.1.16	Determination of antibodies (IGM) to the herpes simplex virus type 1/2*	Study	22.15	17.25	39.40
8.17.9.1.17	Determination of antibodies (IgG) to the herpes simplex virus type 1/2*	Study	22.15	13.84	35.99
8.17.9.1.18.	Determination of IGG Avity to cytomegalovirus	Study	22.15	26.66	48.81
8.17.9.1.19	Determination of IGG Avil to toxoplasm*	Study	22.15	18.78	40.93
8.17.9.1.20	Determination of antibodies (IG G) to AT to Chlamydia pneumoniae in serum	Study	22.15	05/17	39.20
8.17.9.1.21	Determination of antibodies (Ig a) to Mycoplasma	Study	22.15	14.30	36.45
8.17.9.1.22	Determination of antibodies (IG M with absorption) to AT to Mycoplasma Pneumoniae in serum	Study	22.15	17.18	39.33
8.17.9.1.23	Determination of antibodies (IG G) to Mycoplasma pneumoniae in serum	Study	22.15	14.30	36.45
8.17.9.1.24	Determination of antibodies (IG A) to at AT to Chlamydia pneumoniae in serum	Study	22.15	19.40	41.55
8.17.9.1.25	Determination of antibodies (IG m with absorption) to AT to Chlamydia pneumoniae in serum	Study	22.15	20.75	42.90
8.17.9.1.26	Determination of antibodies (m, g) to Sars-Cov-2 in the blood	Study	22.15	11.72	33.87
8.17.9.1.27	Determination of Interlikin L-6	Study	22.15	27.06	49.21
8.17.9.4.1.	Determination of immunoglobulins (antibodies) of one class to chlamydia Trachomatis (IG G) with manual calculation of the positiveness coefficient and antibodies titer*	Study	23.43	15.98	39.41
8.17.9.4.2.	Determination of immunoglobulins (antibodies) of one class to chlamydia Trochomatis (IG A) with manual calculation of the positiveness coefficient and antibodies titer*	Study	23.43	15.92	39.35
8.17.9.4.3.	Determination of immunoglobulins (antibodies) of one class to chlamydia Trochomatis-IGM (with the absorbent of the Russian Federation)*	procedure	23.43	19.36	42.79
9.	Genetic studies
9.7.	Looping tests with glucose (glucosotolerant test-GGT 2 multiple)	Study	4.47	1.64	6.11

Determination of the number of IGG/IgM antibodies to SARS-COV-2 method (FIA)

	Name of the service	Unit of measurement	Rate No VAT	The cost of supplies	Total cost
1	2	3	4	5	6
1. 2.	Registration (preliminary and final) of the material, patient’s passport data and research results in journals and banks or PC GCT*	Study	2.66	0.50	3.16
1. 2. 1.	Registration (provision of results by e -mail)*	Study	2.66	0	2.66
*1	Determination of antibodies to the Covid virus using the ICHROMA analyzer GCT*	Study	15.00	19.58	34.58
*1. 3. 1.	Taking blood from a finger (antibodies)	Study	1.13	1.57	2.70